Affects IBM enterprise identity products used broadly; auth bypass enables remote account takeover and wide-impact unauthorized access.
CVE-2026-19491
Auth bypass in IBM Security Verify allows remote account takeover.
Is CVE-2026-19491 being exploited?
Not confirmed. CVE-2026-19491 does not appear in CISA's Known Exploited Vulnerabilities catalog, which records only exploitation that has been observed and reported publicly. That is evidence of absence of a report, not evidence the flaw is unattacked. EPSS currently estimates a 0.33% probability of exploitation in the next 30 days.
How severe is CVE-2026-19491?
CVE-2026-19491 is rated Critical with a CVSS score of 9.1. Severity describes how bad exploitation would be, not how likely it is: pair it with exploitation evidence before deciding what to patch first.
Is there a patch for CVE-2026-19491?
Yes. A fix has been recorded for CVE-2026-19491. The vendor advisory is the authority on the exact fixed version — apply it from there rather than from a summary.
What does CVE-2026-19491 affect?
CVE-2026-19491 affects IBM Security Verify Access 10.0 - 10.0.9.2, IBM Verify Identity Access 11.0 - 11.0.3. Confirm the exact affected versions against the vendor advisory before deciding you are exposed.
What should I do about CVE-2026-19491?
Apply vendor fixes/mitigations from IBM advisory; restrict access and monitor logs.
Exploitation status reflects CISA's KEV catalog as we last synced it. Check the catalog directly.
Unauthenticated remote attacker can bypass authentication to access accounts, admin functions, and protected resources leading to takeover and data access.
Immediate action required
- affected>= 10.0 and <= 10.0.9.2
- affected>= 10.0 and <= 10.0.9.2
- affected>= 11.0 and <= 11.0.3
- affected>= 11.0 and <= 11.0.3
As published in the CVE Program record. A version outside these ranges is not a statement that it is unaffected — vendors sometimes understate a range, and distribution-backported builds carry upstream numbers that do not reflect what was patched into them.